ArticlePharmaceutics2022
Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 2
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Evaluation of Novel Co-Processed Excipients for Direct Compression Using the Sediment Delivery Model (SeDeM) Expert System.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Design, Molecular Docking,Current pharmaceutical design · 2026Article
- Quality by Design-Driven Formulation Development of Cannabidiol Orally Disintegrating Tablets.Scientifica · 2026Article
- Formulation and Analytical Evaluation of Liquid Cannabidiol Preparations: Comparative Study of Oil-Based Solutions and Emulsions.Pharmaceutics · 2025Article
- Quality by Design Formulation Approach for the Development of Orodispersible Tablets of Dexlansoprazole.Drug design, development and therapy · 2025Article
- 3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract.Gels (Basel, Switzerland) · 2024Article
- Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.International journal of molecular sciences · 2024Review
- Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization,Drug delivery · 2023Article
- Current Challenges and Opportunities for Improved Cannabidiol Solubility.International journal of molecular sciences · 2023Article
- The Influence of the Intergranular Superdisintegrant Performance on New Drotaverine Orodispersible Tablet Formulations.Pharmaceutics · 2023Article
- Article
- Preparation and Evaluation of Directly Compressible Orally Disintegrating Tablets of Cannabidiol Formulated Using Liquisolid Technique.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Orodispersible tablets (ODTs) are pharmaceutical formulations used to obtain fast therapeutic effects, usually recommended for geriatric and pediatric patients due to their improved compliance, bioavailability, ease of administration, and good palatability. This study aimed to develop ODTs with cannabidiol (CBD) phytocannabinoid extracted from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.